Met Life Investment Management, LLC Verve Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 40,173 shares of VERV stock, worth $192,428. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,173
Previous 40,173
-0.0%
Holding current value
$192,428
Previous $196,000
1.02%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding VERV
# of Institutions
187Shares Held
73.4MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$59.2 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$31.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$23.8 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$20.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$19.2 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $287M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...